AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00096070
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00096070
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00801632
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
Trial: NCT03454620
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GC1118 combination with irinotecan
Trial: NCT00937196
Drug: Histaminum hydrochloricum globuli
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00998192
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
Trial: NCT00998192
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
Trial: NCT00392041
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3mg qpm for 12 weeks
Trial: NCT00696722
Drug: placebo + atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo treatment first, atazanavir treatment second~4 day treatment
Trial: NCT00696722
Drug: atazanavir + placebo
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Atazanavir treatment first, placebo treatment second~4 day treatment
Trial: NCT01217359
Drug: Interferon Alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
Trial: NCT03201835
Drug: PNL-THC:CBD soft gelatin capsule
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
Trial: NCT03201835
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spray X 4 actuations
Trial: NCT03201835
Drug: CBD hard capsule dose 1
RxNorm normalized name: methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 hard capsule containing 10 mg CBD
Trial: NCT03201835
Drug: P-PNL-THC:CBD soft gelatin capsule
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
Trial: NCT03201835
Drug: CBD hard capsule dose 2
RxNorm normalized name: methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 hard capsule containing 100 mg CBD
Trial: NCT02072096
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00764738
Drug: Ranibizumab Ophthalmic
RxNorm normalized name: ranibizumab ophthalmic
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg ranibizumab vs 2.0 mg ranibizumab
Trial: NCT01452828
Drug: TR-701 FA single infusion
RxNorm normalized name: Recombinant anti-cdr-bi-single-chain-fv-diphtheria toxin fusion protein
DrugBank: A-dmDT390-bisFv(UCHT1) (DB16307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion, 200 mg daily for 7 days
Trial: NCT03517631
Drug: Low dose busulfan preconditioning
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
Trial: NCT03517631
Drug: Busulfan preconditioning
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
Trial: NCT02072096
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT02072096
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02072096
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02072096
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT02072096
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT02072096
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (SC)
Trial: NCT02072096
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT02072096
Drug: Exenatide once weekly (QW)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02072096
Drug: Exenatide twice daily (BID)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00615823
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
Trial: NCT00730405
Drug: Albaconazole 100mg
RxNorm normalized name: Fluconazole
DrugBank: Albaconazole (DB12073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albaconazole for 36 weeks
Trial: NCT00730405
Drug: Albaconazole 200mg
RxNorm normalized name: Fluconazole
DrugBank: Albaconazole (DB12073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albaconazole for 36 weeks
Trial: NCT00730405
Drug: Albaconazole 400mg
RxNorm normalized name: Fluconazole
DrugBank: Albaconazole (DB12073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albaconazole for 36 weeks
Trial: NCT00730405
Drug: Albaconazole 400mg
RxNorm normalized name: Fluconazole
DrugBank: Albaconazole (DB12073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albaconazole for 24 weeks, Placebo for 12 weeks
Trial: NCT02063620
Drug: Ketamine HCL
RxNorm normalized name: ketamine HCl
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
Trial: NCT03851705
Drug: Inclisiran Sodium for injection
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Trial: NCT00796198
Drug: Xalatan
RxNorm normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Xalatan ophthalmic solution one drop at 10pm
Trial: NCT01496807
Drug: Sylatron
RxNorm normalized name: Sylatron
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sylatron - Once per week for 12 weeks, given as an injection under the skin.
Trial: NCT01496807
Drug: Yervoy
RxNorm normalized name: Yervoy
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
Trial: NCT00885430
Drug: Pico-Salax
RxNorm normalized name: SALIX
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two sachets of Pico-Salax given 5 hours apart
Trial: NCT01464099
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
Trial: NCT04443270
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days.
Trial: NCT01191398
Drug: Atropine (0.01mg/kg)
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
Trial: NCT00216736
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose oral dexamethasone 8mg at time of ED discharge
Trial: NCT03811418
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.
Trial: NCT03811418
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.
Trial: NCT03811418
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.
Trial: NCT01191398
Drug: Glycopyrrolate (0.01mg/kg)
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
Trial: NCT02989519
Drug: dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02989519
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03811418
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death.
Trial: NCT01522820
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO or PEG
Trial: NCT00264966
Drug: ASM8
RxNorm normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00911274
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg Capsule
Trial: NCT03216967
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
Trial: NCT02462681
Drug: paravertebral block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
Trial: NCT01701323
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01701323
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC or IV
Trial: NCT01701323
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00941460
Drug: Temozolomide in both arms
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: initial dose 120 mg/m2 in arm A
Trial: NCT00941460
Drug: Temozolomide in both arms
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: initial dose 80 mg/m2 in arm B
Trial: NCT03639415
Drug: Increasing the Controlled-Release Oxycodone dose frequency
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
Trial: NCT01092845
Drug: PF-04457845 / matched placebo
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04457845 4 mg tablet once daily / matched placebo
Trial: NCT03056118
Drug: 6-month dual anti-platelet therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
Trial: NCT03056118
Drug: 12-month dual anti-platelet therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
Trial: NCT03104725
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00205478
Drug: VX-702
RxNorm normalized name: VX-702
DrugBank: VX-702 (DB05470)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00384020
Drug: Paroxetine (Seroxat)
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00384020
Drug: Escitalopram (Lexapro)
RxNorm normalized name: escitalopram Oral Tablet [Lexapro]
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02256943
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg single dose
Trial: NCT01639872
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
Trial: NCT01639872
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
Trial: NCT02256943
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo 1 mg single dose
Trial: NCT04289948
Drug: Phage
RxNorm normalized name: Oncophage
DrugBank: Viral Macrophage-Inflammatory Protein (DB15748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
Trial: NCT03815305
Drug: Centella Asiatica Extract
RxNorm normalized name: Centella Asiatica Extract
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: centlla asiatica oral drug at 1100 mg dose
Trial: NCT03815305
Drug: Petroleum jelly
RxNorm normalized name: Petroleum Jelly
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaseline album
Trial: NCT01057342
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
Trial: NCT01057342
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
Trial: NCT01057342
Drug: vadimezan
RxNorm normalized name: Vadimezan
DrugBank: Vadimezan (DB06235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
Trial: NCT00440505
Drug: Nicotine (5 mg)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
Trial: NCT00440505
Drug: Nicotine (10 mg)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
Trial: NCT00496470
Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug)
RxNorm normalized name: budesonide / formoterol Metered Dose Inhaler [Symbicort]
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Symbicort (budesonide/formoterol turbuhaler 320/9ug)
Trial: NCT00496470
Drug: Spiriva (tiotropium bromide 18ug)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva (tiotropium bromide 18ug)
Trial: NCT03990454
Drug: SLC-391
RxNorm normalized name: SLC-391
DrugBank: SLC-391 (DB18814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLC-391 is an AXL inhibitor
Trial: NCT00836485
Drug: Ketotifen 4.0% Patch
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
Trial: NCT00836485
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gtt/eye on two separate occasions
Trial: NCT00836485
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gtt/eye on two separate occasions
Trial: NCT00262574
Drug: Nesiritide,
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCI
Trial: NCT04451746
Drug: Combined Oral Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
Trial: NCT00715442
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg by mouth daily for 28 consecutive days
Trial: NCT02351700
Drug: IV Caldolor
RxNorm normalized name: Caldolor
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Caldolor (IV ibuprofen) intraoperatively and postoperatively